485 related articles for article (PubMed ID: 22722224)
21. An update on the management of urinary tract infections in the era of antimicrobial resistance.
Bader MS; Loeb M; Brooks AA
Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
[TBL] [Abstract][Full Text] [Related]
22. Extended-spectrum beta-lactamase-producing organisms.
Falagas ME; Karageorgopoulos DE
J Hosp Infect; 2009 Dec; 73(4):345-54. PubMed ID: 19596491
[TBL] [Abstract][Full Text] [Related]
23. Community-Acquired Uropathogenic
Carmona-Cartaya Y; Hidalgo-Benito M; Borges-Mateus LM; Pereda-Novales N; González-Molina MK; Quiñones-Pérez D
MEDICC Rev; 2022 May; 24(2):20-25. PubMed ID: 35648059
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Cha R
Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
[TBL] [Abstract][Full Text] [Related]
25. Antibacterial activity of fosfomycin against uropathogens.
Sun F; Chen S; Qiu X; Sun Y; Feng W; Chen J; Xia P
Chemotherapy; 2014; 60(3):157-61. PubMed ID: 25792115
[TBL] [Abstract][Full Text] [Related]
26. Increasing prevalence of ciprofloxacin resistance in extended-spectrum-β-lactamase-producing Escherichia coli urinary isolates.
Bonkat G; Müller G; Braissant O; Frei R; Tschudin-Suter S; Rieken M; Wyler S; Gasser TC; Bachmann A; Widmer AF
World J Urol; 2013 Dec; 31(6):1427-32. PubMed ID: 23358791
[TBL] [Abstract][Full Text] [Related]
27. [Increasing prevalence of fosfomycin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates (2005-2009-2011)].
Rodríguez-Avial C; Rodríguez-Avial I; Hernández E; Picazo JJ
Rev Esp Quimioter; 2013 Mar; 26(1):43-6. PubMed ID: 23546462
[TBL] [Abstract][Full Text] [Related]
28. Activity of beta-lactam beta-lactamase inhibitor combinations against extended spectrum Beta-lactamase producing Enterobacteriaceae in urinary isolates.
Afridi FI; Farooqi BJ
J Coll Physicians Surg Pak; 2012 Jun; 22(6):358-62. PubMed ID: 22630093
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of tigecycline and molecular characterization of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates from a university hospital in south-western Germany.
Wienke M; Pfeifer Y; Weissgerber P; Marschal M; Autenrieth IB; Gröbner S
Chemotherapy; 2012; 58(3):241-8. PubMed ID: 22832033
[TBL] [Abstract][Full Text] [Related]
30. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
[TBL] [Abstract][Full Text] [Related]
31. Emergency Department Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Many Patients Have No Identifiable Risk Factor and Discordant Empiric Therapy Is Common.
Frazee BW; Trivedi T; Montgomery M; Petrovic DF; Yamaji R; Riley L
Ann Emerg Med; 2018 Oct; 72(4):449-456. PubMed ID: 29980462
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey.
Demir T; Buyukguclu T
Int J Infect Dis; 2013 Nov; 17(11):e966-70. PubMed ID: 23742831
[TBL] [Abstract][Full Text] [Related]
33. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
[TBL] [Abstract][Full Text] [Related]
34. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections.
Schito GC; Naber KG; Botto H; Palou J; Mazzei T; Gualco L; Marchese A
Int J Antimicrob Agents; 2009 Nov; 34(5):407-13. PubMed ID: 19505803
[TBL] [Abstract][Full Text] [Related]
35. Susceptibility to Fosfomycin and Nitrofurantoin of ESBL-Positive
Park KS; Kim DR; Baek JY; Shin A; Kim KR; Park H; Son S; Cho H; Kim YJ
J Korean Med Sci; 2023 Dec; 38(48):e361. PubMed ID: 38084025
[TBL] [Abstract][Full Text] [Related]
36. Molecular epidemiology and antimicrobial resistance pattern of extended-spectrum-β-lactamase-producing Enterobacteriaceae in Glasgow, Scotland.
Khanna N; Boyes J; Lansdell PM; Hamouda A; Amyes SG
J Antimicrob Chemother; 2012 Mar; 67(3):573-7. PubMed ID: 22169188
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of fosfomycin trometamol and other oral antibiotics against multidrug-resistant uropathogens.
Mezzatesta ML; La Rosa G; Maugeri G; Zingali T; Caio C; Novelli A; Stefani S
Int J Antimicrob Agents; 2017 Jun; 49(6):763-766. PubMed ID: 28390962
[TBL] [Abstract][Full Text] [Related]
38. Susceptibility profile, resistance mechanisms & efficacy ratios of fosfomycin, nitrofurantoin & colistin for carbapenem-resistant
Amladi AU; Abirami B; Devi SM; Sudarsanam TD; Kandasamy S; Kekre N; Veeraraghavan B; Sahni RD
Indian J Med Res; 2019 Feb; 149(2):185-191. PubMed ID: 31219082
[TBL] [Abstract][Full Text] [Related]
39. Prevalence and antibiotic susceptibility pattern of CTX-M type extended-spectrum β-lactamases among clinical isolates of gram-negative bacilli in Jimma, Ethiopia.
Zeynudin A; Pritsch M; Schubert S; Messerer M; Liegl G; Hoelscher M; Belachew T; Wieser A
BMC Infect Dis; 2018 Oct; 18(1):524. PubMed ID: 30342476
[TBL] [Abstract][Full Text] [Related]
40. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood.
Ko KS; Suh JY; Peck KR; Lee MY; Oh WS; Kwon KT; Jung DS; Lee NY; Song JH
Diagn Microbiol Infect Dis; 2007 May; 58(1):111-5. PubMed ID: 17300900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
